Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appeal

June 8, 2026 07:01 AM EDT PharmaLaw Take­da says it ex­pects to take $2.5B hit af­ter Ami­ti­za an­titrust ver­dict, with plans to ap­peal Ayisha Sharma News Reporter Take­da has up­dat­ed its fi­nan­cial re­sults to re­flect costs it could in­cur af­ter los­ing an an­titrust law­suit con­cern­ing its lax­a­tive drug Ami­ti­za. In May, the … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER